These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 26837312

  • 1. BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia.
    Latham S, Bartley PA, Budgen B, Ross DM, Hughes E, Branford S, White D, Hughes TP, Morley AA.
    J Clin Pathol; 2016 Sep; 69(9):817-21. PubMed ID: 26837312
    [Abstract] [Full Text] [Related]

  • 2. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.
    Bartley PA, Ross DM, Latham S, Martin-Harris MH, Budgen B, Wilczek V, Branford S, Hughes TP, Morley AA.
    Int J Lab Hematol; 2010 Dec; 32(6 Pt 1):e222-8. PubMed ID: 20491997
    [Abstract] [Full Text] [Related]

  • 3. Droplet digital PCR for BCR/ABL(P210) detection of chronic myeloid leukemia: A high sensitive method of the minimal residual disease and disease progression.
    Wang WJ, Zheng CF, Liu Z, Tan YH, Chen XH, Zhao BL, Li GX, Xu ZF, Ren FG, Zhang YF, Chang JM, Wang HW.
    Eur J Haematol; 2018 Sep; 101(3):291-296. PubMed ID: 29691899
    [Abstract] [Full Text] [Related]

  • 4. RT-qPCR and RT-Digital PCR: A Comparison of Different Platforms for the Evaluation of Residual Disease in Chronic Myeloid Leukemia.
    Alikian M, Whale AS, Akiki S, Piechocki K, Torrado C, Myint T, Cowen S, Griffiths M, Reid AG, Apperley J, White H, Huggett JF, Foroni L.
    Clin Chem; 2017 Feb; 63(2):525-531. PubMed ID: 27979961
    [Abstract] [Full Text] [Related]

  • 5. A new highly sensitive real-time quantitative-PCR method for detection of BCR-ABL1 to monitor minimal residual disease in chronic myeloid leukemia after discontinuation of imatinib.
    Kitamura H, Tabe Y, Ai T, Tsuchiya K, Yuri M, Misawa S, Horii T, Kawaguchi A, Ohsaka A, Kimura S.
    PLoS One; 2019 Feb; 14(3):e0207170. PubMed ID: 30835732
    [Abstract] [Full Text] [Related]

  • 6. BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia.
    Pagani IS, Dang P, Kommers IO, Goyne JM, Nicola M, Saunders VA, Braley J, White DL, Yeung DT, Branford S, Hughes TP, Ross DM.
    Haematologica; 2018 Dec; 103(12):2026-2032. PubMed ID: 29976745
    [Abstract] [Full Text] [Related]

  • 7. Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.
    McCarron SL, Langabeer SE, Bolger K, Haslam K, Crampe M, Kelly J, Morrell R.
    Med Oncol; 2015 Feb; 32(2):452. PubMed ID: 25579165
    [Abstract] [Full Text] [Related]

  • 8. Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy.
    Salmon M, White HE, Zizkova H, Gottschalk A, Motlova E, Cerveira N, Colomer D, Coriu D, Franke GN, Gottardi E, Izzo B, Jurcek T, Lion T, Schäfer V, Venturi C, Vigneri P, Zawada M, Zuna J, Hovorkova L, Koblihova J, Klamova H, Markova MS, Srbova D, Benesova A, Polivkova V, Zackova D, Mayer J, Roeder I, Glauche I, Ernst T, Hochhaus A, Polakova KM, Cross NCP.
    Leukemia; 2022 Jul; 36(7):1879-1886. PubMed ID: 35676453
    [Abstract] [Full Text] [Related]

  • 9. Quantitative real-time polymerase chain reaction as an efficient molecular tool for detecting minimal residual disease in Moroccan chronic myeloid leukemia patients.
    Moumen A, Dehbi H, Kottwitz D, El Amrani M, Bouchoutrouch N, El Hadi H, Quessar A, Benchekroun S, Nadifi S, Sefrioui H.
    Genet Mol Res; 2015 Feb 06; 14(1):1044-55. PubMed ID: 25730044
    [Abstract] [Full Text] [Related]

  • 10. A rare e13a3 (b2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: The challenges in diagnosis and monitoring minimal residual disease (MRD).
    Duan MH, Li H, Cai H.
    Leuk Res; 2017 Aug 06; 59():8-11. PubMed ID: 28527402
    [Abstract] [Full Text] [Related]

  • 11. Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation.
    Bernardi S, Malagola M, Zanaglio C, Polverelli N, Dereli Eke E, D'Adda M, Farina M, Bucelli C, Scaffidi L, Toffoletti E, Deambrogi C, Stagno F, Bergamaschi M, Franceschini L, Abruzzese E, Divona MD, Gobbi M, Di Raimondo F, Gaidano G, Tiribelli M, Bonifacio M, Cattaneo C, Iurlo A, Russo D.
    Cancer Med; 2019 May 06; 8(5):2041-2055. PubMed ID: 30950237
    [Abstract] [Full Text] [Related]

  • 12. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2003 Sep 06; 17(9):1687-94. PubMed ID: 12970765
    [Abstract] [Full Text] [Related]

  • 13. Clinical implications of conventional cytogenetics, fluorescence in situ hybridization (FISH) and molecular testing in chronic myeloid leukaemia patients in the tyrosine kinase inhibitor era - A review.
    Ankathil R, Ismail SM, Mohd Yunus N, Sulong S, Husin A, Abdullah AD, Hassan R.
    Malays J Pathol; 2020 Dec 06; 42(3):307-321. PubMed ID: 33361712
    [Abstract] [Full Text] [Related]

  • 14. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.
    Leukemia; 2002 Sep 06; 16(9):1579-83. PubMed ID: 12200666
    [Abstract] [Full Text] [Related]

  • 15. A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia.
    Bartley PA, Latham S, Budgen B, Ross DM, Hughes E, Branford S, White D, Hughes TP, Morley AA.
    J Mol Diagn; 2015 Mar 06; 17(2):185-92. PubMed ID: 25554588
    [Abstract] [Full Text] [Related]

  • 16. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu, Turkina AG, Misiurin AV, Aksenova EV, Domracheva EV, Zakharova AV, Khoroshko ND.
    Ter Arkh; 2007 Mar 06; 79(4):49-53. PubMed ID: 17564019
    [Abstract] [Full Text] [Related]

  • 17. Sustained molecular response with nilotinib in imatinib-intolerant chronic myeloid leukaemia with an e19a2 BCR-ABL1 fusion.
    Crampe M, Garry J, Langabeer SE, Murphy PT.
    Hematol Oncol Stem Cell Ther; 2016 Dec 06; 9(4):168-169. PubMed ID: 27352262
    [No Abstract] [Full Text] [Related]

  • 18. Quantitative real-time reverse-transcription polymerase chain reaction for diagnosis of BCR-ABL positive leukemias and molecular monitoring following allogeneic stem cell transplantation.
    Neumann F, Herold C, Hildebrandt B, Kobbe G, Aivado M, Rong A, Free M, Rössig R, Fenk R, Schneider P, Gattermann N, Royer-Pokora B, Haas R, Kronenwett R.
    Eur J Haematol; 2003 Jan 06; 70(1):1-10. PubMed ID: 12631253
    [Abstract] [Full Text] [Related]

  • 19. [Monitoring bcr/abl mRNA levels in imatinib mesylate treated chronic myeloid leukemia patients by real-time quantitative RT-PCR].
    Qin YZ, Ruan GR, Liu YR, Li JL, Fu JY, Wang H, Chang Y, Jiang B, Jiang Q, Jiang H, Qiu JY, Chen SS, Lu DP.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan 06; 26(1):1-5. PubMed ID: 15946498
    [Abstract] [Full Text] [Related]

  • 20. Large amplicon droplet digital PCR for DNA-based monitoring of pediatric chronic myeloid leukaemia.
    Krumbholz M, Goerlitz K, Albert C, Lawlor J, Suttorp M, Metzler M.
    J Cell Mol Med; 2019 Aug 06; 23(8):4955-4961. PubMed ID: 31199062
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.